Trovafloxacin Mesylate
Trovafloxacin mesylate is the mesylate salt of trovafloxacin, a fluoroquinolone antibiotic targeting bacterial DNA gyrase and topoisomerase IV with broad-spectrum activity. The mesylate salt form was used in the oral formulation of the drug. Due to severe hepatotoxicity associated with its use, it was withdrawn from most markets and its clinical use was severely restricted.
Moleküler Ağırlık
512,5000 g/mol
TPSA
163,00 Ų
Etki Mekanizması
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
CS(=O)(=O)O.N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12
InChI
InChI=1S/C20H15F3N4O3.CH4O3S/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24;1-5(2,3)4/h1-4,7,10-11,16H,5-6,24H2,(H,29,30);1H3,(H,2,3,4)/t10-,11+,16+;
Molecular Formula
C21H19F3N4O6S
HBD / HBA
3 / 13
Döndürülebilir Bağlar
3
Ağır Atomlar
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Trovafloxacin mesylate is the mesylate salt of trovafloxacin, a fluoroquinolone antibiotic targeting bacterial DNA gyrase and topoisomerase IV with broad-spectrum activity. The mesylate salt form was used in the oral formulation of the drug. Due to severe hepatotoxicity associated with its use, it was withdrawn from most markets and its clinical use was severely restricted.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Trovafloxacin Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200779. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 62960. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trovafloxacin-mesylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trovafloxacin-mesylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trovafloxacin-mesylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trovafloxacin-mesylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trovafloxacin-mesylate"></drugfyi-drug>